{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:28:36Z","timestamp":1786728516358,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>The tripartite motif-containing protein 26 (TRIM26) is an E3 ubiquitin ligase with strong oncogenic activity in various cancers. However, its role and molecular mechanism in prostate cancer (PCa) remain elusive. To clarify its role in promoting PCa progression, we evaluated TRIM26 expression in cells and clinical specimens using immunohistochemistry and found that TRIM26 was significantly upregulated in PCa tissue. Moreover, high TRIM26 levels predicted a poor prognosis in patients with PCa. Ectopic overexpression of TRIM26 increased PCa cell proliferation and migration, and this activity was suppressed by TRIM26 knockdown. Notably, TRIM26 activated both protein kinase B (AKT)\/mammalian target of the rapamycin (mTOR) and the epithelial\u2013mesenchymal transition (EMT) signaling pathways in PCa cells. Consistent with these findings, TRIM26 knockdown led to decreased activation of these signals. Furthermore, the phosphoinositide 3-kinase (PI3K)\/AKT\/mTOR signaling pathway activated by TRIM26 was attenuated by the PI3K inhibitor S14161. Similarly, cisplatin, a commonly used anti-PCa drug, downregulated TRIM26 and AKT\/mTOR activation, while TRIM26 overexpression reversed AKT\/mTOR inactivation. Finally, this finding was also demonstrated TRIM26 expression strikingly promoted tumor growth and activated AKT\/mTOR signaling in a PCa xenograft. In conclusion, TRIM26 drives PCa malignancy and may be an attractive target for PCa treatment.<\/jats:p>","DOI":"10.4103\/aja202526","type":"journal-article","created":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T04:00:09Z","timestamp":1751947209000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Inhibition of the PI3K\/AKT signaling pathway blocks the oncogenic activity of TRIM26 in prostate cancer cells"],"prefix":"10.4103","volume":"28","author":[{"given":"Yue-Ya","family":"Zhong","sequence":"first","affiliation":[{"name":"The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Disease of Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Huan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Disease of Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Ye","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Disease of Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiu-Min","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Ming","family":"He","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Disease of Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Liang","family":"Mao","sequence":"additional","affiliation":[{"name":"The Key Laboratory of Advanced Interdisciplinary Studies, the First Affiliated Hospital of Guangzhou Medical University & Guangdong Provincial Key Laboratory of Protein Modification and Disease of Guangzhou Medical University, Guangzhou 511436, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215000, China"},{"name":"Department of Urology, Jinling Hospital of Nanjing University, Nanjing 210002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"key":"R1-20260122","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer:a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"R3-20260122","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/emboj\/20.9.2140","article-title":"The tripartite motif family identifies cell compartments","volume":"20","author":"Reymond","year":"2001","journal-title":"EMBO J"},{"key":"R4-20260122","doi-asserted-by":"crossref","first-page":"e1004726","DOI":"10.1371\/journal.ppat.1004726","article-title":"TRIM26 negatively regulates interferon-\u03b2production and antiviral response through polyubiquitination and degradation of nuclear IRF3","volume":"11","author":"Wang","year":"2015","journal-title":"PLoS Pathog"},{"key":"R5-20260122","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrmicro1248","article-title":"TRIM family proteins:retroviral restriction and antiviral defence","volume":"3","author":"Nisole","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"R6-20260122","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/s41418-021-00754-7","article-title":"Deubiquitinase USP39 and E3 ligase TRIM26 balance the level of ZEB1 ubiquitination and thereby determine the progression of hepatocellular carcinoma","volume":"28","author":"Li","year":"2021","journal-title":"Cell Death Differ"},{"key":"R7-20260122","doi-asserted-by":"crossref","first-page":"109366","DOI":"10.1016\/j.cbi.2021.109366","article-title":"Knockdown of TRIM26 inhibits the proliferation, migration and invasion of bladder cancer cells through the Akt\/GSK3\u03b2\/\u03b2-catenin pathway","volume":"337","author":"Xie","year":"2021","journal-title":"Chem Biol Interact"},{"key":"R8-20260122","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1038\/s41467-021-26653-6","article-title":"Competitive binding of E3 ligases TRIM26 and WWP2 controls SOX2 in glioblastoma","volume":"21","author":"Mahlokozera","year":"2021","journal-title":"Nat Commun"},{"key":"R9-20260122","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1002\/cam4.1537","article-title":"A regulatory mutant on TRIM26 conferring the risk of nasopharyngeal carcinoma by inducing low immune response","volume":"7","author":"Lyu","year":"2018","journal-title":"Cancer Med"},{"key":"R10-20260122","doi-asserted-by":"crossref","first-page":"19019","DOI":"10.1002\/jcp.28541","article-title":"Overexpression of TRIM26 suppresses the proliferation, metastasis, and glycolysis in papillary thyroid carcinoma cells","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol"},{"key":"R11-20260122","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.7150\/ijbs.81726","article-title":"TRIM26 promotes non-small cell lung cancer survival by inducing PBX1 degradation","volume":"19","author":"Sun","year":"2023","journal-title":"Int J Biol Sci"},{"key":"R12-20260122","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41401-021-00662-z","article-title":"TRIM25 activates AKT\/mTOR by inhibiting PTEN via K63-linked polyubiquitination in non-small cell lung cancer","volume":"43","author":"He","year":"2022","journal-title":"Acta Pharmacol Sin"},{"key":"R13-20260122","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1074\/jbc.RA118.006057","article-title":"Inhibition of the deubiquitinase USP9x induces pre-B cell homeobox 1 (PBX1) degradation and thereby stimulates prostate cancer cell apoptosis","volume":"294","author":"Liu","year":"2019","journal-title":"J Biol Chem"},{"key":"R14-20260122","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1111\/j.1349-7006.2011.02008.x","article-title":"Normal prostate-derived stromal cells stimulate prostate cancer development","volume":"102","author":"Peng","year":"2011","journal-title":"Cancer Sci"},{"key":"R15-20260122","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1016\/j.ajpath.2014.06.022","article-title":"Stromal androgen receptor in prostate development and cancer","volume":"184","author":"Singh","year":"2014","journal-title":"Am J Pathol"},{"key":"R16-20260122","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.bbrc.2015.05.117","article-title":"TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis","volume":"463","author":"Wang","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"R17-20260122","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.1007\/s00210-024-03112-9","article-title":"A bibliometric analysis of the application of the PI3K-AKT-mTOR signaling pathway in cancer","volume":"397","author":"Deng","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R18-20260122","doi-asserted-by":"crossref","first-page":"563.e561","DOI":"10.1016\/j.clgc.2021.07.014","article-title":"Targeting the PI3K-AKT-mTOR pathway in castration resistant prostate cancer:a review article","volume":"19","author":"Cham","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"R19-20260122","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.toxlet.2014.05.003","article-title":"A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3","volume":"228","author":"Shi","year":"2014","journal-title":"Toxicol Lett"},{"key":"R20-20260122","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1158\/1535-7163.MCT-21-0320","article-title":"HER2 mediates PSMA\/mGluR1-driven resistance to the DS-7423 dual PI3K\/mTOR inhibitor in PTEN wild-type prostate cancer models","volume":"21","author":"G\u00f3mez","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"R21-20260122","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood-2010-05-284810","article-title":"A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway","volume":"117","author":"Mao","year":"2011","journal-title":"Blood"},{"key":"R22-20260122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.biochi.2019.08.003","article-title":"Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process","volume":"165","author":"Karimi Roshan","year":"2019","journal-title":"Biochimie"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:28:08Z","timestamp":1786724888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aja202526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aja202526","relation":{},"ISSN":["1745-7262","1008-682X"],"issn-type":[{"value":"1745-7262","type":"print"},{"value":"1008-682X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"2024-07-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-07","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}